GSK plc GSK
50.31 USD -0.10 (-0.21%)
Nov 6, 2026, 11:25 AM EST
48.98 Day range 50.44
45.81 52-week range 61.70
- YTD
- +2.58%
- 1 year
- +6.80%
Analyst view
Consensus: hold
Hold
Price target (mean) 59.12 +17.5% upside
Now 50.31
- Target (low)
- 49.00
- Target (mean)
- 59.12
- Target (high)
- 70.00
Ratings (0m) 9 3 buy · 5 hold · 1 sell
- Strong buy1
- Buy2
- Hold5
- Sell1
- Strong sell0
Recommendation trend
- This month 9
- 1 month ago 9
- 2 months ago 8
- 3 months ago 8
Earnings and revenue estimates
Consensus for the coming quarters and fiscal years
| Period | EPS estimate | Low – high | Year ago | EPS growth | Revenue estimate | Revenue growth | Analysts |
|---|---|---|---|---|---|---|---|
| Current quarter | 0.73676 | 0.72585 – 0.74766 | 0.69843 | +5.5% | 8.87B | +2.9% | 2 |
| Current year | 4.76 | 4.72 – 4.80 | 4.71 | +1.1% | 33.84B | +3.6% | 4 |
| Next year | 4.96 | 4.83 – 5.15 | 4.76 | +4.1% | 35.27B | +4.2% | 5 |
Upgrades and downgrades
The latest rating changes
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Oct 29, 2026 | Jefferies | Downgrade | Buy | Hold |
| Jan 6, 2026 | Barclays | Downgrade | Equal-Weight | Underweight |
| Nov 12, 2024 | Jefferies | Downgrade | Buy | Hold |
| Oct 31, 2024 | Guggenheim | Downgrade | Buy | Neutral |
| Jul 8, 2024 | UBS | Downgrade | Buy | Neutral |
| Jul 2, 2024 | Jefferies | Maintained | Buy | Buy |
| May 30, 2024 | Goldman Sachs | Initiated | — | Neutral |
| Mar 4, 2024 | Guggenheim | Upgrade | Neutral | Buy |
| Jan 23, 2024 | Morgan Stanley | Initiated | — | Equal-Weight |
| Jan 3, 2024 | Jefferies | Upgrade | Hold | Buy |